The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen
Introduction Acetaminophen is a commonly used analgesic and antipyretic drug, and is frequently used to study gastric emptying. Due to its high permeability and high solubility, acetaminophen can be used as a pharmacologic model for medications with similar characteristics. The objective of this stu...
Gespeichert in:
Veröffentlicht in: | Advances in therapy 2011-08, Vol.28 (8), p.650-660 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Introduction
Acetaminophen is a commonly used analgesic and antipyretic drug, and is frequently used to study gastric emptying. Due to its high permeability and high solubility, acetaminophen can be used as a pharmacologic model for medications with similar characteristics. The objective of this study was to assess the effect of liraglutide on the pharmacokinetics (PK) of acetaminophen in patients with type 2 diabetes.
Methods
This was a randomized, placebo-controlled, two-period crossover trial in which subjects with type 2 diabetes received placebo or liraglutide. After steady state PK of liraglutide 1.8 mg/ placebo were established, a single dose of acetaminophen 1 g was administered at the time of liraglutide C
max
(maximum concentration). The PK profile of acetaminophen was assessed at 18 time points during the 8-hour post-dosing period. Placebo and liraglutide were considered equivalent with respect to area under the curve (AUC)
0−∞
and AUC
0−480
min of acetaminophen if the 90% CI for the ratio was fully contained within the limits of 0.80 to 1.25.
Results
All subjects (
n
=18; mean [SD] age 59 [7] years, body mass index [BMI] 29.7 [4.2] kg/m
2
, and glycated hemoglobin [HbA
1c
] 7.8% [0.6%]) completed the study. Equivalence was demonstrated between liraglutide 1.8 mg at steady state and placebo, with respect to acetaminophen AUC
0−∞
(estimated ratio 1.04; 90% CI: 0.97, 1.10) and acetaminophen AUC
0-480
min (estimated ratio 0.95; 90% CI: 0.89, 1.01). During liraglutide, a lower C
max
was observed (estimated ratio 0.69; 90% CI: 0.56, 0.85) and the median acetaminophen t
max
occurred 15 minutes later compared with placebo.
Conclusion
The overall exposure of acetaminophen following a 1 g dose was comparable for subjects taking liraglutide or placebo, and the clinical impact of the lower C
max
and delay in absorption of acetaminophen was considered to be transient and small, and without clinical relevance. No adjustment for acetaminophen is recommended when used concomitantly with liraglutide. |
---|---|
ISSN: | 0741-238X 1865-8652 |
DOI: | 10.1007/s12325-011-0044-y |